EPCAM and cancer: Intraperitoneal injections (2 nmol/mouse/every two days) of the bi-specific CD44-EpCAM aptamer in mice bearing ovarian OVCAR8 tumors resulted in increased cancer cell apoptosis and a significant reduction in tumor growth [150].